The systemic virotherapy strategy involves not only the direct delivery of therapeutic payloads encoded by viruses to tumors, but also the modification of the tumor microenvironment, aiming to target both primary and metastatic lesions. At the ongoing American Society of Clinical Oncology (ASCO) meeting, researchers from Calidi Biotherapeutics Inc. reported the development of a novel approach using a selected and engineered tumor-selective strain of vaccinia virus.
Calidi Biotherapeutics Inc. has released promising preclinical results for its systemic Rtnova platform showing its ability to successfully deliver transient gene therapy payloads to targeted tumors. Moreover, the company’s tumor-specific virotherapy has demonstrated efficacy in killing over 60 different tumor cell lines.
Calidi Biotherapeutics Inc. has conducted studies in animals to determine the safety and efficacy of oncolytic virotherapy (OV) with CLD-201 (Supernova-1) to treat solid tumors.
Calidi Biotherapeutics Inc. has announced a collaboration with Siga Technologies Inc. to support the development of Calidi’s systemic and targeted Rtnova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.
The California Institute for Regenerative Medicine (CIRM) has awarded Calidi Biotherapeutics Inc. a US$3.1 million grant to support continued development of the company's Supernova-1 (SNV-1) preclinical program through IND application. The grant was awarded to Calidi to support IND-enabling studies, finalize manufacturing and the completion of Calidi's IND application for the SNV-1 program.
